SURPASS-CVOT: A comparison of Tirzepatide and Dulaglutide

Show notes

Watch the full episode on YouTube or listen on your preferred podcast platform to explore the SURPASS-CVOT trial results. In this episode, EASD TV Host, Vivienne Parry sits with Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD Independent Advisor and McMaster University) as they explain how tirzepatide performs compared to dulaglutide in cardioprotective outcomes. The experts unpack the trial’s implications for clinical practice, highlighting how outcomes trials like this inform personalised medicine, integrate care between diabetologists and cardiologists, and generate new hypotheses in areas such as liver disease, cognitive function, and obesity management

Learn more about the trial and its relevance for clinical practice, multi-specialist care, and future research directions, including the integration of cardiovascular, liver, and cognitive outcomes into comprehensive diabetes management.

Explore the latest EASD 2025 Annual Meeting presentations and view our speakers’ profiles:

  1. Prof. Tina Vilsbøll
  2. Prof. Hertzel Gerstein

For more content from our previous episodes, visit our podcast archive.

New comment

Your name or nickname, will be shown publicly
At least 10 characters long
By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.